Detection of autoantibodies in bronchoalveolar lavage in patients with diffuse interstitial lung disease

Salvador-Corres, Iñaki; Quirant‐Sánchez, Bibiana; Teniente‐Serra, Aina; Centeno, Carmen; Moreno, Amàlia; Rodríguez-Pons, Laura; Serra-Mitjá, Pere; García-Núñez, Marian; Martı́nez-Cáceres, Eva; Rosell, Antoni; Olivé, Alejandro; Portillo, Karina

doi:10.1016/j.arbr.2021.03.009

Cited by 6 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, BAL analysis could offer more than cytological cell count. Cell gene expression, lung microbiota, microRNA signatures or proteomic analysis in BAL samples have shown promising results that could improve ILD characterization, including PLCH [ 20 ].…”

Section: Discussionmentioning

confidence: 99%

Bronchoalveolar cytokine profile differentiates Pulmonary Langerhans cell histiocytosis patients from other smoking-related interstitial lung diseases

Barril,

Acebo,

Millan-Billi

et al. 2023

Respir Res

View full text Add to dashboard Cite

Background Pulmonary Langerhans cell histiocytosis (PLCH) is a rare interstitial lung disease (ILD) associated with smoking, whose definitive diagnosis requires the exclusion of other forms of ILD and a compatible surgical lung biopsy. Bronchoalveolar lavage (BAL) is commonly proposed for the diagnosis of ILD, including PLCH, but the diagnostic value of this technique is limited. Here, we have analyzed the levels of a panel of cytokines and chemokines in BAL from PLCH patients, in order to identify a distinct immune profile to discriminate PLCH from other smoking related-ILD (SR-ILD), and comparing the results with idiopathic pulmonary fibrosis (IPF) as another disease in which smoking is considered a risk factor. Methods BAL samples were collected from thirty-six patients with different ILD, including seven patients with PLCH, sixteen with SR-ILD and thirteen with IPF. Inflammatory profiles were analyzed using the Human Cytokine Membrane Antibody Array. Principal component analysis (PCA) was performed to reduce dimensionality and protein–protein interaction (PPI) network analysis using STRING 11.5 database were conducted. Finally, Random forest (RF) method was used to build a prediction model. Results We have found significant differences (p < 0.05) on thirty-two cytokines/chemokines when comparing BAL from PLCH patients with at least one of the other ILD. Four main groups of similarly regulated cytokines were established, identifying distinct sets of markers for each cluster. Exploratory analysis using PCA (principal component analysis) showed clustering and separation of patients, with the two first components capturing 69.69% of the total variance. Levels of TARC/CCL17, leptin, oncostatin M (OSM) and IP-10/CXCL10 were associated with lung function parameters, showing positive correlation with FVC. Finally, random forest (RF) algorithm demonstrates that PLCH patients can be differentiated from the other ILDs based solely on inflammatory profile (accuracy 96.25%). Conclusions Our results show that patients with PLCH exhibit a distinct BAL immune profile to SR-ILD and IPF. PCA analysis and RF model identify a specific immune profile useful for discriminating PLCH.

show abstract

Section: Discussionmentioning

confidence: 99%

Bronchoalveolar cytokine profile differentiates Pulmonary Langerhans cell histiocytosis patients from other smoking-related interstitial lung diseases

Barril,

Acebo,

Millan-Billi

et al. 2023

Respir Res

View full text Add to dashboard Cite

show abstract

“…Autoantibodies play a crucial role in CTD-ILD as their presence is related to the pathogenesis of the lung tissue damage; nevertheless, their presence in BAL has been poorly investigated. A recent study by Salvador-Corres et al 37 evaluated anti-ENAs in 155 BAL of patients with suspected ILD and found positive autoantibodies in 19 of them, including anti Ro52, anti-Ro60, CENP-B, anti La, Jo-1, Sm-RNP, anti SL70. Fourteen were diagnosed with CTD-ILD, three with IPAF, one with NSIP, and one with silicosis.…”

Section: Bal In Ctd-related Ildmentioning

confidence: 99%

Bronchoalveolar lavage and lung biopsy in connective tissue diseases, to do or not to do?

Tomassetti

Colby

Wells

et al. 2021

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Bronchoalveolar lavage and lung biopsy (LBx) are helpful in patients with connective tissue diseases (CTD) and interstitial lung diseases (ILD) regardless of cause, including infectious, noninfectious, immunologic, or malignant. The decision whether to perform only bronchoalveolar lavage (BAL), and eventually a subsequent LBx in case of a nondiagnostic lavage, or one single bronchoscopy combining both sampling methods depends on the clinical suspicion, on patient’s characteristics (e.g. increased biopsy risk) and preferences, and on the resources and biopsy techniques available locally (e.g. regular forceps versus cryobiopsy). In CTD-ILD, BAL has major clinical utility in excluding infections and in the diagnosis of specific patterns of acute lung damage (e.g. alveolar hemorrhage, diffuse alveolar damage, and organizing pneumonia). LBx is indicated to exclude neoplasm or diagnose lymphoproliferative lung disorders that in CTD patients are more common than in the general population. Defining BAL cellularity and characterizing the CTD-ILD histopathologic pattern by LBx can be helpful in the differential diagnosis of cases without established CTD [e.g. ILD preceding full-blown CTD, interstitial pneumonia with autoimmune features (IPAF)], but the prognostic and theragnostic role of those findings remains unclear. Few studies in the pretranscriptomics era have investigated the diagnostic and prognostic role of BAL and LBx in CTD-ILD, and it is reasonable to hypothesize that future studies conducted applying innovative techniques on BAL and LBx might open new and unexpected avenues in pathogenesis, diagnosis, and treatment approach to CTD-ILD. This is particularly desirable now that a new drug treatment era is emerging, in which we have more than one therapeutic choice (immunosuppressive agents, antifibrotic drugs, and biological agents). We hope that future research will pave the path toward precision medicine providing data for a more accurate ILD-CTD endotyping that will guide the physicians through targeted therapeutic choices, rather than to the approximative approach ‘one drug fits them all’.

show abstract

Autoimmunity in the Study of Interstitial Lung Disease: Are Serological Test Enough?

Castellví¹,

Vidal²,

Valenzuela³

2022

Archivos de Bronconeumología

View full text Add to dashboard Cite

Detection of autoantibodies in bronchoalveolar lavage in patients with diffuse interstitial lung disease

Cited by 6 publications

References 34 publications

Bronchoalveolar cytokine profile differentiates Pulmonary Langerhans cell histiocytosis patients from other smoking-related interstitial lung diseases

Bronchoalveolar cytokine profile differentiates Pulmonary Langerhans cell histiocytosis patients from other smoking-related interstitial lung diseases

Bronchoalveolar lavage and lung biopsy in connective tissue diseases, to do or not to do?

Autoimmunity in the Study of Interstitial Lung Disease: Are Serological Test Enough?

Contact Info

Product

Resources

About